LACTOLOGY FOUNDATION

Dexlansoprazole (ATC A02BC06) is a proton pump inhibitor used for acid‑related gastrointestinal disorders, with relevant toxicological concerns and a lactation profile that generally argues against use during breastfeeding.

Pharmacological class and indications

Dexlansoprazole is the R‑enantiomer of lansoprazole and belongs to the ATC group A02BC – proton pump inhibitors, with specific code A02BC06.
It inhibits gastric hydrogen/potassium‑ATPase in parietal cells, thereby suppressing gastric acid secretion.
Clinically, it is indicated for erosive esophagitis, maintenance of healed erosive esophagitis, symptomatic gastroesophageal reflux disease, and related hypersecretory states.
Typical oral doses are 30–60 mg delayed‑release capsules once daily, with treatment durations usually limited to weeks or a few months depending on indication.

Toxicology and safety profile

Dexlansoprazole shares the class toxicology of PPIs, with common adverse effects including headache, dizziness, diarrhea, abdominal pain, nausea, vomiting, flatulence and general weakness.
Serious risks reported with prolonged or high‑dose PPI therapy include hypomagnesemia, increased risk of osteoporosis‑related fractures (including spine fractures), vitamin B12 deficiency, Clostridioides difficile–associated diarrhea, interstitial nephritis and allergic reactions including anaphylaxis and skin reactions.
Long‑term use beyond 12 months has been associated with an increased risk of lymphoproliferative and skeletal complications in general PPI toxicology assessments, and most guidelines recommend avoiding chronic, unreviewed therapy.
Overdose experience is limited; available data suggest mainly dose‑related exacerbation of known adverse effects, and standard supportive care with poison‑control consultation is recommended in suspected overdose.

Drug interactions and special populations

Dexlansoprazole is extensively metabolized by hepatic CYP450 isoenzymes (particularly CYP2C19 and CYP3A4), and thus exhibits multiple pharmacokinetic interactions.
It may increase exposure or effects of drugs with narrow therapeutic indices or overlapping metabolism, such as diazepam, phenytoin, ciclosporin, tacrolimus, digoxin and certain antifungals and antiretrovirals.
By raising gastric pH, dexlansoprazole can reduce gastrointestinal absorption and efficacy of pH‑dependent drugs such as ketoconazole, itraconazole, ampicillin, oral iron preparations and mycophenolate mofetil.
Clinically important attenuation of efficacy has been reported or suspected with some antiplatelet agents (e.g. clopidogrel) and certain protease inhibitors (e.g. atazanavir, nelfinavir, rifampin co‑therapy), requiring careful risk‑benefit assessment in these combinations.
Use requires caution in patients with pre‑existing liver disease, established hypomagnesemia, osteoporosis risk, or in those receiving digitalis, where PPI‑induced electrolyte changes may potentiate digitalis toxicity.

Pregnancy and lactation (toxico‑lactological perspective)

Historically, dexlansoprazole has been labeled as FDA pregnancy Category B in some jurisdictions, indicating absence of clear teratogenicity in animal studies and limited human data, although the letter category system is now being phased out in favor of narrative risk summaries.
Under current FDA Pregnancy and Lactation Labeling Rule (PLLR), risk information is presented narratively, emphasizing available human and animal data on fetal and maternal outcomes rather than a single letter category.
Available data suggest that systemic exposure occurs during pregnancy and that dexlansoprazole should be used only when the expected maternal benefit clearly outweighs potential fetal risks, particularly in the first trimester.

Regarding lactation, dexlansoprazole is expected to be excreted into breast milk to some extent due to its systemic bioavailability and physicochemical properties, although human milk concentration data are very limited.
The parent compound lansoprazole has been categorized in your local toxico‑lactation system as category IV (not compatible with breastfeeding), and the same restrictive category has been assigned to dexlansoprazole, reflecting a precautionary stance based on class effects and lack of robust lactation pharmacokinetic data.
Potential concerns for the breastfed infant include altered gastric acidity, effects on mineral and vitamin absorption, and theoretical risks related to long‑term PPI exposure; consequently, dexlansoprazole is considered incompatible with breastfeeding in your toxico‑lactology framework, and alternative therapies with better characterized lactation safety should be preferred.
If acid‑suppressive therapy is unavoidable in a breastfeeding mother, agents with more favorable or better documented lactation profiles (and ideally non‑PPI options) should be evaluated first, alongside non‑pharmacological measures.

Web‑page style structure (content only)

Title

Dexlansoprazole (ATC A02BC06): Toxicology and Lactation Safety Monograph.

Sections

• Overview
  Dexlansoprazole is a proton pump inhibitor (PPI) classified under ATC code A02BC06, indicated for erosive esophagitis and gastroesophageal reflux disease.
• Mechanism of action
  It directly inhibits the gastric H+/K+-ATPase in parietal cells, leading to profound and sustained suppression of gastric acid secretion.
• Clinical indications and dosing
  Approved indications include healing and maintenance of erosive esophagitis and treatment of symptomatic GERD, usually at oral doses of 30–60 mg once daily for limited treatment courses.
• Toxicological profile
  Common adverse reactions are headache, dizziness, gastrointestinal discomfort and diarrhea, while long‑term use may contribute to hypomagnesemia, vitamin B12 deficiency, bone fractures, C. difficile infection and renal or allergic complications.
• Drug interactions
  Dexlansoprazole is metabolized via CYP450, interacts with drugs such as diazepam, phenytoin, ciclosporin, tacrolimus, digoxin and certain antifungals and antiretrovirals, and reduces absorption of pH‑dependent medicines like ketoconazole, itraconazole, ampicillin, oral iron and mycophenolate mofetil.
• Special populations
  Use requires caution in hepatic impairment, in patients at risk of osteoporosis or hypomagnesemia, and in those on drugs with narrow therapeutic windows or strong pH‑dependent absorption.
• Pregnancy
  Historical classification as Category B has been superseded by narrative PLLR labeling; use during pregnancy should be reserved for situations where benefits outweigh potential risks and after consideration of non‑pharmacological and alternative pharmacological options.
• Lactation
  Due to limited human data, expected passage into breast milk, and theoretical infant risks, dexlansoprazole is assigned to toxico‑lactation category IV (not compatible with breastfeeding) in your local framework, mirroring the assessment for lansoprazole.

Simple comparison table (PPIs context)

*Lansoprazole row reflects your existing classification rather than full monograph detail.